Administrative initiatives for reducing inappropriate prescribing of psychotropic drugs in nursing homes: How successful have they been?

Drugs and Aging

Volumn 22, Issue 4, 2005, Pages 339-351

  Hughes, Carmel M ^a   Lapane, Kate L ^b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANXIOLYTIC AGENT; BARBITURIC ACID DERIVATIVE; BELLADONNA ALKALOID; CARISOPRODOL; CHLORDIAZEPOXIDE; CHLORPHENIRAMINE; CHLORPROMAZINE; CHLORPROPAMIDE; CHLORZOXAZONE; CLORAZEPATE DIPOTASSIUM; CYCLOBENZAPRINE; CYPROHEPTADINE; DANTROLENE; DEXCHLORPHENIRAMINE; DIAZEPAM; DICYCLOVERINE; DIGOXIN; DIPHENHYDRAMINE; DIPYRIDAMOLE; DISOPYRAMIDE; DOXEPIN; ERGOT ALKALOID; FLURAZEPAM; HALOPERIDOL; HYDROXYZINE; HYOSCYAMINE; HYPNOTIC AGENT; INDOMETACIN; LORAZEPAM; MEPROBAMATE; METHOCARBAMOL; METHYLDOPA; MUSCLE RELAXANT AGENT; NEUROLEPTIC AGENT; ORPHENADRINE; OXAZEPAM; PENTAZOCINE; PETHIDINE; PHENOBARBITAL; PROMETHAZINE; PROPANTHELINE BROMIDE; PSYCHOTROPIC AGENT; RESERPINE; TEMAZEPAM; THIORIDAZINE; TICLOPIDINE; TRIAZOLAM; TRIMETHOBENZAMIDE; TRIPELENNAMINE; ZOLPIDEM;

DELUSIONAL DISORDER; DRUG USE; HEALTH CARE MANAGEMENT; HEALTH CARE QUALITY; HEALTH SERVICE; HUMAN; LONG TERM CARE; MOOD DISORDER; NURSING HOME; OUTCOMES RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; RESIDENTIAL CARE; REVIEW; SCHIZOPHRENIA;

AGED; DRUG UTILIZATION; EFFICIENCY, ORGANIZATIONAL; HUMANS; MEDICATION ERRORS; NURSING HOMES; PRESCRIPTIONS, DRUG; PSYCHOTROPIC DRUGS; QUALITY INDICATORS, HEALTH CARE;

EID: 18544380722     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200522040-00006     Document Type: Review

References (79)

1. Institute of Medicine. Improving the quality of long-term care. Washington, DC: National Academy Press, 2001
2. Fahey T, Montgomery AA, Barnes J, et al. Quality of care for elderly residents in nursing homes and elderly people living at home: controlled observational study. BMJ 2003; 326: 580-4
3. United States General Accounting Office. Nursing Homes. Additional steps needed to strengthen enforcement of federal quality standards: Report to Congressional Requesters, Washington DC, March 1999. GAO/HES-99-46 [online]. Available from URL: http://www.gao.gov [Accessed 2004 Jun 30]
4. United States General Accounting Office. California nursing homes: care problems persist despite federal and state oversight. Report to Congressional Requesters, Washington DC, July 1998: GAO/HES-98-202 [online]. Available from URL: http://www.gao.gov/archive/1998/he98202.pdf [Accessed 2005 Mar 12]
5. Institute of Medicine. Improving the quality of care in nursing homes. Washington, DC: National Academy Press, 1986
6. Elon R, Pawlson LG. The impact of OBRA on medical practices within nursing facilities. J Am Geriatr Soc 1992; 40: 958-63
7. Facility Guide for the Nursing Home Quality Indicators: National Data Systems. Center for Health Systems Research and Analysis, University of Wisconsin, Madison [online]. Available from URL: http://www.cms.hhs.gov/ medicaid/ltcsp/manu al.pdf [Accessed 2003 Dec 22]
8. Beers MH, Ouslander JG, Rollinger I, et al. Explicit criteria for determining inappropriate medication use in nursing home residents. Arch Intern Med 1991; 151: 1825-32
9. Beers MH. Explicit criteria for determining inappropriate medication use by the elderly. Arch Intern Med 1997; 157: 1531-6
10. Pick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults. Arch Intern Med 2003; 163: 2716-24
11. Omnibus Budget Reconciliation Act of 1987 (OBRA 87). Public Law 100-203, Subtitle C: Nursing Home Reform, Washington DC, 1987 Dec 22
12. Cooper JW. Geriatric drug therapy interventions. J Geriatr Drug Ther 1997; 11: 3-26
13. Bootman JL, Johnson DL, Cox E. The health care costs of drug-related morbidity and mortality in nursing facilities. Arch Intern Med 1997; 157: 1531-6
14. Ray WA, Federspiel CF, Schaffer W. Antipsychotic drug use in nursing homes: epidemiologic evidence of misuse. Am J Public Health 1980; 70: 485-91
15. Beers MH, Avorn J, Soumerai SB, et al. Psychoactive medication use in intermediate-care facilities. JAMA 1988; 260: 3016-20
16. Buck JA. Psychotropic drug practice in nursing homes. J Am Geriatr Soc 1988; 36: 409-18
17. Avorn J, Dreyer P, Connelly K, et al. Use of psychoactive medication and the quality of care in rest homes. N Engl J Med 1989; 320: 227-32
18. Beardsley RS, Larson DB, Burns BJ, et al. Prescribing of psychotropics in elderly nursing home patients. J Am Geriatr Soc 1989; 37: 327-30
19. Ingman SR, Lawson IR, Pierpaoli PG, et al. A survey of the prescribing and administration of drugs in a long-term care institution for the elderly. J Am Geriatr Soc 1975; 23: 309-16
20. Kalchthaler T, Coccaro E, Lichtiger S. Incidence of polypharmacy in a long-term care facility. J Am Geriatr Soc 1977; 25: 308-13
21. Morgan K, Gilleard CJ, Reive A. Hypnotic usage in residential homes for the elderly: a prevalence and longitudinal analysis. Age Ageing 1982; 11: 229-34
22. Stewart R, May FE, Moore MT, et al. Changing patterns of psychotropic drug use in the elderly: a five-year update. Drug Intell Clin Pharm 1989; 23: 610-3
23. Stoudemire A, Smith DA. OBRA regulations and the use of psychotropic drugs in long-term care facilities: impact and implications for geropsychiatric care. Gen Hosp Psychiatry 1996; 18: 77-94
24. Eichmann MA, Griffin BP, Lyons JS, et al. An estimation of the impact of OBRA-87 on nursing home care in the United States. Hosp Community Psychiatry 1992; 43: 781-9
25. Streim JE, Katz IR. Federal regulations and the care of patients with dementia in the nursing home. Med Clin North Am 1994; 78: 895-909
26. Llorente MD, Olsen EJ, Leyva O, et al. Use of antipsychotic drugs in nursing homes: current compliance with OBRA regulations. J Am Geriatr Soc 1998; 46: 198-201
27. Tessier EG. Evaluating drug therapy: principles and practices for long-term care providers. In: Tessier EG, Gaziano G, editors. Geriatric drug handbook for long-term care. Baltimore (MD): Williams and Wilkins, 1993: 165-74
28. Health Care Financing Administration (HCFA; 1995); State Operations Manual. Baltimore (MD): Health Care Financing Administration, 1995
29. Rovner BW, Edelman BA, Cox MP, et al. The impact of antipsychotic drug regulations on psychotropic prescribing practices in nursing homes. Am J Psychiatry 1992; 149: 1390-2
30. Semla TP, Palla K, Poddig B, et al. Effect of the Omnibus Reconciliation Act 1987 on antipsychotic prescribing in nursing home residents. J Am Geriatr Soc 1994; 42: 648-52
31. Shorr RI, Fought RL, Ray WA. Changes in antipsychotic drug use in nursing homes during implementation of the OBRA-87 regulations. JAMA 1994; 271: 358-63
32. Garrard J, Chen V, Dowd B. The impact of the 1987 Federal regulations on the use of psychotropic drugs in Minnesota nursing homes. Am J Public Health 1995; 85: 771-6
33. Hawes C, Mor V, Phillips CD, et al. The OBRA-87 nursing home regulations and implementation of the Resident Assessment Instrument: effects on process quality. J Am Geriatr Soc 1997; 45: 977-85
34. Lantz MS, Giambanco V, Buchalter EN. A ten-year review of the effect of OBRA-87 on psychotropic prescribing practices in an academic nursing homes. Psychiatr Serv 1996; 47: 951-5
35. Borson S, Doane K. The impact of OBRA-87 on psychotropic drug prescribing in skilled nursing facilities. Psychiatr Serv 1997; 48: 1289-96
36. Hughes CM, Lapane KL, Mor V, et al. The impact of legislation on psychotropic drug use in nursing homes: a cross-national perspective. J Am Geriatr Soc 2000; 48: 931-7
37. Clark TR. Quality indicators and the nursing facility survey: implications for the consultant pharmacist. Available from URL: http://www.ascp.com [Accessed 2003 Dec 16]
38. Stuck AE, Beers MH, Steiner A, et al. Inappropriate medication use in community-residing older people. Arch Intern Med 1994; 154: 2195-200
39. Dhalla IA, Anderson GM, Mamdani MM, et al. Inappropriate prescribing before and after nursing home admission. J Am Geriatr Soc 2002; 50: 995-1000
40. Mor V, Berg K, Angelleli J, et al. The quality of quality measurement in US nursing homes. Spec No 43. Gerontologist 2003; 2: 37-46
41. NIH Consensus Development Panel on Depression in late life: diagnosis and treatment of depression in late life. JAMA 1992; 268: 1018-24
42. Rovner BW, German PS, Brant LJ, et al. Depression and mortality in nursing homes. JAMA 1991; 265: 993-6
43. Brown MN, Lapane KL, Luisi AF. The management of depression in elderly nursing home residents. J Am Geriatr Soc 2002; 50: 69-76
44. Heston LL, Garrard J, Makris L, et al. Inadequate treatment of depressed nursing home elderly. J Am Geriatr Soc 1992; 40: 1117-22
45. Lapane KL, Hughes CM. An evaluation of the Prospective Payment System on antidepressant use in nursing home residents. Med Care 2004; 42: 48-58
46. Medicare. Nursing home compare [online]. Available from URL: http://www.medicare.gov/NHCompare/homes [Accessed 2004 Jun 30]
47. Gambassi G, Forman DE, Lapane KL, et al. Management of heart failure among very old individuals living in long-term care: has the voice of trials spread? Am Heart J 2000; 139: 85-93
48. Lapane KL, Fernandez H, Friedman J. Prevalence, clinical correlates and pharmacologic treatment of Parkinson's disease patients living in long term care. Pharmacotherapy 1999; 19: 1321-7
49. Spooner JJ, Lapane KL, Hume AL, et al. Management of diabetes in long term care. J Clin Epidemiol 2001; 54: 525-30
50. Cody M, Beck C, Svarstad BL. Challenges to the use of nonpharmacologic interventions in nursing homes. Psychiatr Serv 2002; 53: 1402-6
51. Centers for Medicare and Medicaid Services. Nursing home quality initiative [online]. Available from URL: http://www.cms.hhs.gov/quality/nhqi [Accessed 2004 Jun 30]
52. Bernabei R, Gambassi G, Lapane KL, et al. Management of pain in elderly patients with cancer. JAMA 1998; 279: 1877-82
53. Lapane KL, Barbour MM, Van Haaren A, et al. Anti-ischemic therapy in patients with coronary heart disease living in long term care. Pharmacotherapy 1999; 19: 627-34
54. Quilliam BJ, Lapane KL. Pharmacologic treatment of stroke in long term care. Stroke 2001; 32: 1385-93
55. Hughes CM, Lapane K, Mor V. The impact of legislation on nursing home care in the United States: lessons for the United Kingdom. BMJ 1999; 319: 1060-3
56. Snowdon J, Vaughan R, Miller R, et al. Psychotropic drug use in Sydney nursing homes. Med J Aust 1995; 163: 70-2
57. Van Dijk KN, de Vries CS, van den Berg PB, et al. Drug utilisation in Dutch nursing homes. Eur J Clin Pharmacol 2000; 55: 765-71
58. Ruths S, Straand J, Nygaard HA. Multidisciplinary medication review in nursing home residents: what are the most significant drug-related problems? The Bergen District Nursing Home (BEDNURS) study. Qual Saf Health Care 2003; 12: 176-80
59. Holmquist IB, Svensson B, Haglund P. Psychotropic drugs in nursing and old age homes: relationships between needs of care and mental health status. Eur J Clin Pharmacol 2003; 59: 669-76
60. Oborne CA, Hooper R, Li KC, et al. An indicator of appropriate neuroleptic prescribing in nursing homes. Age Ageing 2002; 31: 435-9
61. Fahey T, Montgomery AA, Barnes J, et al. Quality of care for elderly residents in nursing homes and elderly people living at home: controlled observational study. BMJ 2003; 326: 580-4
62. McGrath AM, Jackson GA. Survey of neuroleptic prescribing in residents of nursing homes in Glasgow. BMJ 1996; 312: 611-2
63. Avorn JL. The elderly and drug policy: coming of age. Health Aff 1990; 9: 6-19
64. Smith DA. New rules for prescribing psychotropics in nursing homes. Geriatrics 1990; 45: 44-56
65. Beers MH, Fingold SF, Ouslander JG, et al. Characteristics and quality of prescribing by doctors practicing in nursing homes. J Am Geriatr Soc 1993; 41: 802-7
66. Kane RL, Garrard J. Changing physician prescribing practices. JAMA 1994; 271: 393-4
67. Schmidt I, Claesson CB, Westerholm B, et al. The impact of regular multidisciplinary team interventions on psychotropic prescribing in Swedish nursing homes. J Am Geriatr Soc 1998; 46: 77-82
68. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990; 47: 533-43
69. Ray WA, Blazer DG, Schaffner W, et al. Reducing antipsychotic drug prescribing for nursing home patients: a controlled trial of the effect of an educational visit. Am J Public Health 1987; 77: 1448-50
70. Avorn J, Soumerai SB, Everitt DE, et al. A randomized trial of a program to reduce the use of psychoactive drugs in nursing homes. N Engl J Med 1992; 327: 168-73
71. Ray WA, Taylor JA, Meador KG, et al. Reducing antipsychotic drug use in nursing homes: a controlled trial of provider education. Arch Intern Med 1993; 153: 713-21
72. Meador KG, Taylor JA, Thapa PB, et al. Predictors of antipsychotic withdrawal or dose reduction in a randomized controlled trial of provider education. J Am Geriatr Soc 1997; 45: 207-10
73. Office of the Inspector General, US Department of Health and Human Services (DHHS). Prescription drug use in nursing homes. Washington, DC: DHHS. In: Report 2: an inside view by consultant pharmacists. 1997 Nov. Report no.: OEI-06-96-00081
74. Hanlon JT, Schmader KE, Ruby CM, et al. Suboptimal prescribing in older inpatients and outpatients. J Am Geriatr Soc 2001; 49: 200-9
75. Cameron K, Feinberg JL, Lapane KL. Fleetwood project Phase III moves forward. Consultant Pharmacist 2002; 17: 181-98
76. Gurwitz JH, Field TS, Avorn J, et al. Incidence and preventability of adverse drug events in nursing homes. Am J Med 2000; 109: 87-94
77. Drazen J. Inserting government between patient and physician. N Engl J Med 2004; 350: 178-9
78. Schnelle JF, Cruise PA, Rahman A, et al. Developing rehabilitative non-pharmacologic interventions for long-term care: technology transfer, acceptance and maintenance issues. J Am Geriatr Soc 1998; 46: 771-7
79. Svarstadt BL, Mount JK, Bigelow W. Variations in treatment culture and nursing home response to drug regulation. Psychiatr Serv 2001; 53: 666-72